356 related articles for article (PubMed ID: 37397394)
1. Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy.
Cipri S; Del Baldo G; Fabozzi F; Boccuto L; Carai A; Mastronuzzi A
Front Oncol; 2023; 13():1204829. PubMed ID: 37397394
[TBL] [Abstract][Full Text] [Related]
2. Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas.
Garcia MA; Solomon DA; Haas-Kogan DA
Future Oncol; 2016 Jun; 12(12):1493-506. PubMed ID: 27072750
[TBL] [Abstract][Full Text] [Related]
3. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
4. Pediatric low-grade gliomas can be molecularly stratified for risk.
Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
[TBL] [Abstract][Full Text] [Related]
5. Pediatric hemispheric cerebellar low-grade gliomas: clinical approach, diagnosis, and management challenges-experience at a tertiary care children's hospital.
Cicutti SE; Del Río RJ; Cáceres A; Gonzalez Ramos JD
Childs Nerv Syst; 2024 Apr; ():. PubMed ID: 38607550
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
7. Advances in pediatric gliomas: from molecular characterization to personalized treatments.
Sathyakumar S; Martinez M; Perreault S; Legault G; Bouffet E; Jabado N; Larouche V; Renzi S
Eur J Pediatr; 2024 Jun; 183(6):2549-2562. PubMed ID: 38558313
[TBL] [Abstract][Full Text] [Related]
8. A Molecular Update and Review of Current Trials in Paediatric Low-Grade Gliomas.
Al-Jilaihawi S; Lowis S
Pediatr Neurosurg; 2023; 58(5):290-298. PubMed ID: 37604126
[TBL] [Abstract][Full Text] [Related]
9. An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.
Lassaletta A; Zapotocky M; Bouffet E; Hawkins C; Tabori U
Childs Nerv Syst; 2016 Oct; 32(10):1789-97. PubMed ID: 27659822
[TBL] [Abstract][Full Text] [Related]
10. 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.
Thomas DL
Chin Clin Oncol; 2023 Feb; 12(1):7. PubMed ID: 36922356
[TBL] [Abstract][Full Text] [Related]
11. Unsupervised machine learning using K-means identifies radiomic subgroups of pediatric low-grade gliomas that correlate with key molecular markers.
Haldar D; Kazerooni AF; Arif S; Familiar A; Madhogarhia R; Khalili N; Bagheri S; Anderson H; Shaikh IS; Mahtabfar A; Kim MC; Tu W; Ware J; Vossough A; Davatzikos C; Storm PB; Resnick A; Nabavizadeh A
Neoplasia; 2023 Feb; 36():100869. PubMed ID: 36566592
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers and targeted therapy in pediatric low-grade glioma.
de Blank P; Fouladi M; Huse JT
J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
[TBL] [Abstract][Full Text] [Related]
13. Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management.
Samples DC; Mulcahy Levy JM; Hankinson TC
Front Surg; 2022; 9():884250. PubMed ID: 35599811
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
15. Management of pediatric low-grade glioma.
de Blank P; Bandopadhayay P; Haas-Kogan D; Fouladi M; Fangusaro J
Curr Opin Pediatr; 2019 Feb; 31(1):21-27. PubMed ID: 30531227
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.
Bergthold G; Bandopadhayay P; Hoshida Y; Ramkissoon S; Ramkissoon L; Rich B; Maire CL; Paolella BR; Schumacher SE; Tabak B; Ferrer-Luna R; Ozek M; Sav A; Santagata S; Wen PY; Goumnerova LC; Ligon AH; Stiles C; Segal R; Golub T; Grill J; Ligon KL; Chan JA; Kieran MW; Beroukhim R
Neuro Oncol; 2015 Nov; 17(11):1486-96. PubMed ID: 25825052
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.
Ramkissoon LA; Horowitz PM; Craig JM; Ramkissoon SH; Rich BE; Schumacher SE; McKenna A; Lawrence MS; Bergthold G; Brastianos PK; Tabak B; Ducar MD; Van Hummelen P; MacConaill LE; Pouissant-Young T; Cho YJ; Taha H; Mahmoud M; Bowers DC; Margraf L; Tabori U; Hawkins C; Packer RJ; Hill DA; Pomeroy SL; Eberhart CG; Dunn IF; Goumnerova L; Getz G; Chan JA; Santagata S; Hahn WC; Stiles CD; Ligon AH; Kieran MW; Beroukhim R; Ligon KL
Proc Natl Acad Sci U S A; 2013 May; 110(20):8188-93. PubMed ID: 23633565
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics and therapeutic targets of pediatric low-grade gliomas.
Tateishi K; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2019 Apr; 36(2):74-83. PubMed ID: 30929113
[TBL] [Abstract][Full Text] [Related]
19. Paediatric Gliomas: BRAF and Histone H3 as Biomarkers, Therapy and Perspective of Liquid Biopsies.
Tan JY; Wijesinghe IVS; Alfarizal Kamarudin MN; Parhar I
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557011
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
